<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We evaluated the effect of <z:chebi fb="0" ids="9753">troglitazone</z:chebi> (given orally 400 mg/day) on <z:hpo ids='HP_0000833'>glucose intolerance</z:hpo> and on the plasma levels of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor-alpha (TNF-alpha) in 12 <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> for 12 weeks </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="9753">Troglitazone</z:chebi> significantly decreased fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi>, serum C-<z:chebi fb="7" ids="16670">peptide</z:chebi>, serum insulin and HbA1c levels </plain></SENT>
<SENT sid="2" pm="."><plain>Plasma levels of TNF-alpha were significantly reduced by <z:chebi fb="0" ids="9753">troglitazone</z:chebi> administered for 8 and 12 weeks </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="9753">Troglitazone</z:chebi> administration significantly improved <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, but did not affect pancreatic beta-cell function as evaluated by the homeostasis model assessment (HOMA) </plain></SENT>
<SENT sid="4" pm="."><plain>In the present study, we reported for the first time that <z:chebi fb="0" ids="9753">troglitazone</z:chebi> administration significantly reduces plasma levels of TNF-alpha in <z:mp ids='MP_0001261'>obese</z:mp> patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>